Novartis International AG (NVS) Q4 2019 Earnings Call Transcript

Novartis International AG (NVS) Q4 2019 Earnings Call Transcript

So if we move to Slide 5, as you saw in 2019, we really delivered an outstanding performance across the company.. We want to be a focused medicines company powered by advanced therapy platforms and data science.. A broad-based medicines portfolio, which we believe is the largest medicines company purely focused on the discovery and broad access to medicines in the world.. Moving to Slide 7, when you look at innovation, one of our key pillars, I think, we demonstrated this year that we are on the right track and really have developed the depth of a pipeline that can enable us to grow in the long-term.. Now moving to Slide 8, 2019 was truly a breakthrough year for that innovation with five NME approvals, which we believe is a record for a company in the industry, at least in recent years, six if you include one of our tropical medicine approvals, 30 major submissions around the world, and 30 clinical data readouts.. Now moving to Slide 9, when you look at catalysts for 2020, another full year of catalysts, major approvals, including the expected approval of ofatumumab, which we filed in December and used a priority review voucher.. Our